170 related articles for article (PubMed ID: 26645239)
21. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis.
Thompson EM; Hielscher T; Bouffet E; Remke M; Luu B; Gururangan S; McLendon RE; Bigner DD; Lipp ES; Perreault S; Cho YJ; Grant G; Kim SK; Lee JY; Rao AAN; Giannini C; Li KKW; Ng HK; Yao Y; Kumabe T; Tominaga T; Grajkowska WA; Perek-Polnik M; Low DCY; Seow WT; Chang KTE; Mora J; Pollack IF; Hamilton RL; Leary S; Moore AS; Ingram WJ; Hallahan AR; Jouvet A; Fèvre-Montange M; Vasiljevic A; Faure-Conter C; Shofuda T; Kagawa N; Hashimoto N; Jabado N; Weil AG; Gayden T; Wataya T; Shalaby T; Grotzer M; Zitterbart K; Sterba J; Kren L; Hortobágyi T; Klekner A; László B; Pócza T; Hauser P; Schüller U; Jung S; Jang WY; French PJ; Kros JM; van Veelen MC; Massimi L; Leonard JR; Rubin JB; Vibhakar R; Chambless LB; Cooper MK; Thompson RC; Faria CC; Carvalho A; Nunes S; Pimentel J; Fan X; Muraszko KM; López-Aguilar E; Lyden D; Garzia L; Shih DJH; Kijima N; Schneider C; Adamski J; Northcott PA; Kool M; Jones DTW; Chan JA; Nikolic A; Garre ML; Van Meir EG; Osuka S; Olson JJ; Jahangiri A; Castro BA; Gupta N; Weiss WA; Moxon-Emre I; Mabbott DJ; Lassaletta A; Hawkins CE; Tabori U; Drake J; Kulkarni A; Dirks P; Rutka JT; Korshunov A; Pfister SM; Packer RJ; Ramaswamy V; Taylor MD
Lancet Oncol; 2016 Apr; 17(4):484-495. PubMed ID: 26976201
[TBL] [Abstract][Full Text] [Related]
22. Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.
Rekhtman N; Pietanza MC; Hellmann MD; Naidoo J; Arora A; Won H; Halpenny DF; Wang H; Tian SK; Litvak AM; Paik PK; Drilon AE; Socci N; Poirier JT; Shen R; Berger MF; Moreira AL; Travis WD; Rudin CM; Ladanyi M
Clin Cancer Res; 2016 Jul; 22(14):3618-29. PubMed ID: 26960398
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
[TBL] [Abstract][Full Text] [Related]
24. Age-related mutations and chronic myelomonocytic leukemia.
Mason CC; Khorashad JS; Tantravahi SK; Kelley TW; Zabriskie MS; Yan D; Pomicter AD; Reynolds KR; Eiring AM; Kronenberg Z; Sherman RL; Tyner JW; Dalley BK; Dao KH; Yandell M; Druker BJ; Gotlib J; O'Hare T; Deininger MW
Leukemia; 2016 Apr; 30(4):906-13. PubMed ID: 26648538
[TBL] [Abstract][Full Text] [Related]
25. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.
Morin RD; Assouline S; Alcaide M; Mohajeri A; Johnston RL; Chong L; Grewal J; Yu S; Fornika D; Bushell K; Nielsen TH; Petrogiannis-Haliotis T; Crump M; Tosikyan A; Grande BM; MacDonald D; Rousseau C; Bayat M; Sesques P; Froment R; Albuquerque M; Monczak Y; Oros KK; Greenwood C; Riazalhosseini Y; Arseneault M; Camlioglu E; Constantin A; Pan-Hammarstrom Q; Peng R; Mann KK; Johnson NA
Clin Cancer Res; 2016 May; 22(9):2290-300. PubMed ID: 26647218
[TBL] [Abstract][Full Text] [Related]
26. [Retrospective NGS Study in High-risk Hereditary Cancer Patients at Masaryk Memorial Cancer Institute].
Macháčková E; Hazova J; Sťahlová Hrabincová E; Vašíčková P; Navrátilová M; Svoboda M; Foretová L
Klin Onkol; 2016; 29 Suppl 1():S35-45. PubMed ID: 26691941
[TBL] [Abstract][Full Text] [Related]
27. The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis.
Joshi S; Tolkunov D; Aviv H; Hakimi AA; Yao M; Hsieh JJ; Ganesan S; Chan CS; White E
Cell Rep; 2015 Dec; 13(9):1895-908. PubMed ID: 26655904
[TBL] [Abstract][Full Text] [Related]
28. TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
Koehler K; Liebner D; Chen JL
Ann Oncol; 2016 Mar; 27(3):539-43. PubMed ID: 26646755
[TBL] [Abstract][Full Text] [Related]
29. Molecular Subtypes of Pulmonary Large-cell Neuroendocrine Carcinoma Predict Chemotherapy Treatment Outcome.
Derks JL; Leblay N; Thunnissen E; van Suylen RJ; den Bakker M; Groen HJM; Smit EF; Damhuis R; van den Broek EC; Charbrier A; Foll M; McKay JD; Fernandez-Cuesta L; Speel EM; Dingemans AC;
Clin Cancer Res; 2018 Jan; 24(1):33-42. PubMed ID: 29066508
[No Abstract] [Full Text] [Related]
30. Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
Inamura K; Yokouchi Y; Kobayashi M; Ninomiya H; Sakakibara R; Nishio M; Okumura S; Ishikawa Y
Cancer Med; 2017 Oct; 6(10):2347-2356. PubMed ID: 28925087
[TBL] [Abstract][Full Text] [Related]
31. Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.
Metro G; Ricciuti B; Chiari R; Baretti M; Falcinelli L; Giannarelli D; Sidoni A; Mountzios G; Crinò L; Bellezza G; Rebonato A; Ferolla P; Toschi L
Lung Cancer; 2016 May; 95():82-7. PubMed ID: 27040856
[TBL] [Abstract][Full Text] [Related]
32. Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre.
Huang H; Xu C; Gao J; Li B; Qin T; Xu Z; Ren S; Zhang Y; Jiao M; Qu S; Pan L; Hu N; Liu J; Cai W; Zhang Y; Wu D; Zhang P; Gale RP; Huang G; Zhou J; Shi L; Xiao Z
Blood Cancer J; 2020 Aug; 10(8):83. PubMed ID: 32801296
[TBL] [Abstract][Full Text] [Related]
33. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
[TBL] [Abstract][Full Text] [Related]
34. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
[TBL] [Abstract][Full Text] [Related]
35. Identifying Circulating Tumor DNA Mutation Profiles in Metastatic Breast Cancer Patients with Multiline Resistance.
Hu ZY; Xie N; Tian C; Yang X; Liu L; Li J; Xiao H; Wu H; Lu J; Gao J; Hu X; Cao M; Shui Z; Xiao M; Tang Y; He Q; Chang L; Xia X; Yi X; Liao Q; Ouyang Q
EBioMedicine; 2018 Jun; 32():111-118. PubMed ID: 29807833
[TBL] [Abstract][Full Text] [Related]
36. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
Montalban-Bravo G; Takahashi K; Patel K; Wang F; Xingzhi S; Nogueras GM; Huang X; Pierola AA; Jabbour E; Colla S; Gañan-Gomez I; Borthakur G; Daver N; Estrov Z; Kadia T; Pemmaraju N; Ravandi F; Bueso-Ramos C; Chamseddine A; Konopleva M; Zhang J; Kantarjian H; Futreal A; Garcia-Manero G
Oncotarget; 2018 Feb; 9(11):9714-9727. PubMed ID: 29515765
[TBL] [Abstract][Full Text] [Related]
37. New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management.
Derks JL; Leblay N; Lantuejoul S; Dingemans AC; Speel EM; Fernandez-Cuesta L
J Thorac Oncol; 2018 Jun; 13(6):752-766. PubMed ID: 29454048
[TBL] [Abstract][Full Text] [Related]
38. Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model.
Gangat N; Mudireddy M; Lasho TL; Finke CM; Nicolosi M; Szuber N; Patnaik MM; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
Am J Hematol; 2018 May; 93(5):691-697. PubMed ID: 29417633
[TBL] [Abstract][Full Text] [Related]
39. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Zehir A; Benayed R; Shah RH; Syed A; Middha S; Kim HR; Srinivasan P; Gao J; Chakravarty D; Devlin SM; Hellmann MD; Barron DA; Schram AM; Hameed M; Dogan S; Ross DS; Hechtman JF; DeLair DF; Yao J; Mandelker DL; Cheng DT; Chandramohan R; Mohanty AS; Ptashkin RN; Jayakumaran G; Prasad M; Syed MH; Rema AB; Liu ZY; Nafa K; Borsu L; Sadowska J; Casanova J; Bacares R; Kiecka IJ; Razumova A; Son JB; Stewart L; Baldi T; Mullaney KA; Al-Ahmadie H; Vakiani E; Abeshouse AA; Penson AV; Jonsson P; Camacho N; Chang MT; Won HH; Gross BE; Kundra R; Heins ZJ; Chen HW; Phillips S; Zhang H; Wang J; Ochoa A; Wills J; Eubank M; Thomas SB; Gardos SM; Reales DN; Galle J; Durany R; Cambria R; Abida W; Cercek A; Feldman DR; Gounder MM; Hakimi AA; Harding JJ; Iyer G; Janjigian YY; Jordan EJ; Kelly CM; Lowery MA; Morris LGT; Omuro AM; Raj N; Razavi P; Shoushtari AN; Shukla N; Soumerai TE; Varghese AM; Yaeger R; Coleman J; Bochner B; Riely GJ; Saltz LB; Scher HI; Sabbatini PJ; Robson ME; Klimstra DS; Taylor BS; Baselga J; Schultz N; Hyman DM; Arcila ME; Solit DB; Ladanyi M; Berger MF
Nat Med; 2017 Jun; 23(6):703-713. PubMed ID: 28481359
[TBL] [Abstract][Full Text] [Related]
40. Systematic Functional Annotation of Somatic Mutations in Cancer.
Ng PK; Li J; Jeong KJ; Shao S; Chen H; Tsang YH; Sengupta S; Wang Z; Bhavana VH; Tran R; Soewito S; Minussi DC; Moreno D; Kong K; Dogruluk T; Lu H; Gao J; Tokheim C; Zhou DC; Johnson AM; Zeng J; Ip CKM; Ju Z; Wester M; Yu S; Li Y; Vellano CP; Schultz N; Karchin R; Ding L; Lu Y; Cheung LWT; Chen K; Shaw KR; Meric-Bernstam F; Scott KL; Yi S; Sahni N; Liang H; Mills GB
Cancer Cell; 2018 Mar; 33(3):450-462.e10. PubMed ID: 29533785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
